mk 767 has been researched along with farglitazar in 1 studies
| Studies (mk 767) | Trials (mk 767) | Recent Studies (post-2010) (mk 767) | Studies (farglitazar) | Trials (farglitazar) | Recent Studies (post-2010) (farglitazar) |
|---|---|---|---|---|---|
| 32 | 0 | 10 | 35 | 3 | 5 |
| Protein | Taxonomy | mk 767 (IC50) | farglitazar (IC50) |
|---|---|---|---|
| Peroxisome proliferator-activated receptor gamma | Homo sapiens (human) | 0.121 | |
| Peroxisome proliferator-activated receptor alpha | Homo sapiens (human) | 2.0435 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, PJ; Henke, BR; Sternbach, DD; Willson, TM | 1 |
1 review(s) available for mk 767 and farglitazar
| Article | Year |
|---|---|
The PPARs: from orphan receptors to drug discovery.
Topics: Animals; Diabetes Mellitus; Drug Design; Humans; Hyperlipidemias; Hypertension; Inflammation; Ligands; Models, Molecular; Neoplasms; Nuclear Proteins; Obesity; Receptors, Cytoplasmic and Nuclear; Transcription Factors | 2000 |